dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 23, 2026

Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions

View original at finance.yahoo.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Snowflake's DCF model fair value is $236.22 per share, implying the stock is trading at a 28.9% discount

    60% confidence

  • Snowflake is 113.1% overvalued based on most popular narrative

    60% confidence

  • The valuation narrative could crack if competitive pressure from Databricks intensifies or if Snowflake's losses and stock based compensation continue to weigh on sentiment

    60% confidence

  • Snowflake is a company that is growing fast and holding a lot of cash, while spending remains high and seeing significant increase in customer revenue

    60% confidence

  • Snowflake's fair value is $78.83 per share based on the most followed valuation narrative

    60% confidence

Data points we hold from this source

Snowflake Inc. · fair value dcf236.22 USD
Snowflake Inc. · fair value narrative78.83 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Snowflake (SNOW) Valuation Check As Project SnowWork Expands Its Enterprise AI Ambitions: Source | Via News | fr.via.news